Objective: Ambulatory status has been shown to be an important predictor of postoperative morbidity and mortality for a variety of surgical procedures. We sought to assess contemporary practice patterns in treating critical limb ischemia (CLI) and outcomes based on ambulatory status.
Peripheral arterial disease (PAD) has a prevalence of 3% to 10% and may lead to significant morbidity. 1 The most severe form of PAD is critical limb ischemia (CLI), defined by rest pain or tissue loss. There are 500 to 1000 reported cases of CLI per million per year. 2 Revascularization for CLI can be performed by percutaneous vascular interventions (PVIs) or open vascular surgery, including lower extremity bypass (LEB). PVI often involves balloon angioplasty or stenting; open vascular surgery often includes endarterectomy, arterial bypass, or both. [3] [4] [5] The optimal treatment for patients with CLI is controversial. 6 Both endovascular and open operations are commonly performed to treat CLI, but there is much debate as to which treatment specific patients should receive. Ambulatory and functional status has been shown to be an important predictor of postoperative morbidity and mortality for patients undergoing treatment for CLI. [7] [8] [9] [10] [11] [12] In fact, it is often one of the strongest predictors of periprocedural complications. In addition, ambulatory status has been shown to be a predictor of choice of revascularization strategy as patients with impaired ambulatory status and more comorbidities are more likely to be offered PVI rather than LEB. 13 Nevertheless, it is unclear as to which option is best for patients with impaired ambulatory status. Our goal was to assess current practice patterns of limb revascularization and outcomes stratified by ambulatory status. To gauge contemporary, real-world data, we queried the Vascular Quality Initiative (VQI) to assess the functional status of patients with CLI and to analyze postoperative outcomes for patients undergoing PVI and LEB. 
METHODS
The VQI collects perioperative and long-term data about vascular surgery from >350 academic and community hospitals across North America.
14 The VQI database was started in 2010 and prospectively collects data that include >100 clinical, demographic, and treatment-specific variables. 15 We then excluded those who had both PVI and LEB, leaving 17,688. We prospectively separated patients into three preoperative ambulatory statuses: ambulatory, ambulatory with assistance, and nonambulatory. In the VQI, ambulatory was defined as capable of independent ambulation, including walking with a prosthesis. Ambulatory with assistance was defined as requiring assistance, such as with a cane, walker, or person, for ambulation. Nonambulatory, a composite category that we created, comprises the use of a wheelchair as the predominant means of getting around or being bedridden.
Outcomes of interest were hospital and 30-day mortality, long-term mortality, and 1-year combined amputation and death. These outcomes were assessed for each of the three ambulatory statuses between patients receiving PVI and LEB treatments. Survival in the VQI is determined by Social Security information, and reinterventions are dependent on follow-up and assessment. Demographics, comorbidities, and perioperative outcomes in patients with CLI treated by PVI or LEB were compared for each ambulatory status using the t-test for continuous measures and the c 2 test for categorical measures. One-year morbidity assessment was motivated by proximity to the procedure and limited long-term follow-up. A total of 2610 subjects had 1-year morbidity data.
Multivariable logistic regression analyses of mortality (5-year), amputation or death (1-year), and major adverse limb events (MALEs, defined as amputation or reintervention) or death (1-year) were performed for the three ambulatory statuses stratified by procedure. The adjusted hazard ratios and corresponding 95% confidence intervals were reported. For all multivariable models, the covariates were selected if different (at the .2 level) across the groups or clinically important and in both types of multivariable models, including demographics (age, gender, race, smoking, and preadmission living status), medical history of the patient (hypertension, diabetes, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, previous cardiac interventions, dialysis, history of bypass, PVI, and major amputation), and procedure characteristics (PVI or LEB; target artery; urgency; indication; postoperative use of aspirin, statin, and P2Y 12 antagonist). Backward elimination procedure was used for each model with .5 level to stay to construct parsimonious models. Data analyses were performed using SAS 9.3 software (SAS Institute, Cary, NC).
RESULTS
There were 17,688 eligible patients with CLI and infrainguinal PAD: 11,522 ambulatory patients, 4443 ambulatory with assistance patients, and 1723 nonambulatory patients. For ambulatory patients, 7295 (63.3%) were treated with PVI and 4227 (37.7%) were treated with LEB. For ambulatory with assistance patients, 2992 (67.3%) were treated with PVI and 1451 (32.7%) were treated with LEB. Of the nonambulatory patients, 1332 (77.3%) were treated with PVI and 391 (22.7%) with LEB. The use of procedures was significantly different across ambulatory status groups (P < .01; Fig) . Demographics and comorbidities of the cohort are listed in Tables I  and II . Across all ambulatory statuses, patients treated with PVI were older and had overall more comorbidities. Nonambulatory patients were less likely to live at home preoperatively, were more likely to be on dialysis, and were more likely to have had a previous amputation. Ambulatory patients were more likely to undergo elective PVI, to have tissue loss as an indication for intervention, and to use clopidogrel, and they were less likely to be taking aspirin and statin medications (Table III) . Treatment details for ambulatory with assistance and nonambulatory patients demonstrated similar differences between PVI and LEB, except for case urgency (Table IV) . As functional status declined, patients had more perioperative complications for both PVI and LEB, although more so for LEB (Table V) .
ARTICLE HIGHLIGHTS
The unadjusted 30-day mortality outcomes for PVI patients were 1.5% for ambulatory patients, 3% for ambulatory with assistance patients, and 4.7% for nonambulatory patients. For LEB, 30-day mortality was 1.7% for ambulatory patients, 3.1% for ambulatory with assistance patients, and 4.9% for nonambulatory patients (Table V) . On univariate analysis, worsening ambulatory status was associated with higher wound, cardiac, pulmonary, and renal complications and mortality.
Multivariate analysis showed that for PVI cohorts, poorer ambulatory status predicted mortality (Table VI) . LEB patients who were nonambulatory were also at independently higher risk for mortality. For PVI and LEB, worsening ambulatory status predicted high amputation or death (Table VII) . MALE or death was higher for PVI in nonambulatory patients and for LEB in ambulatory with assist and nonambulatory patients (Table VIII) . Table IX shows the effect of indication and tissue loss vs rest pain on mortality, amputation or death, and MALE or death.
DISCUSSION
Ambulatory status was an independent predictor of higher mortality for both PVI and LEB independent of the fact that ambulatory with assistance and nonambulatory patients had higher rates of comorbidities and perioperative complications. PVI was more commonly used than LEB to treat patients with CLI, and increasingly so as ambulatory status declined. Across all ambulatory statuses, patients treated with PVI tended to have more comorbidities than those treated with LEB. These findings are consistent with the overall analysis of PVI and LEB in the VQI. 13 These comorbidities may contribute to selection bias in comparing the higher rate of mortality in patients receiving PVI than that of those receiving LEB for all ambulatory statuses. Ambulatory status was shown to independently affect mortality, amputation or death, and MALE or death on multivariable analysis. Many studies have attempted to find predictors of outcomes for patients undergoing CLI treatment. Previously reported data have shown that ambulatory status, among others variables, such as age and prior contralateral limb amputations, is an important predictor of revascularization outcomes. 17, 18 Functional status has consistently been shown to be a risk factor for poor morbidity and mortality outcomes, as have protracted length of stay and readmission. 7, 9, 10 These results confirm that ambulatory status is indeed a robust predictor of perioperative and long-term outcomes for patients treated with PVI and LEB. Postoperatively, particularly with bypass, patients have a decrease in their functional status that could take a Prospective analysis with patients randomized to treatment type in the Best Surgery vs Best Endovascular Therapy in Critical Limb Ischemia (BEST-CLI) trial may provide better insight in treating patients with CLI and impaired ambulatory status; however, results will not be available for several years. 20 Currently, the VQI
prospectively collects robust data to analyze contemporary clinical practices in the treatment of CLI. 13 This study is a retrospective analysis of CLI treatment in the VQI, and there are limitations that must be accounted for. Although mortality is an objective measure in the VQI as it is linked to Social Security data, reintervention and amputation measures may be biased by loss of follow-up by the surgeon. However, this reflects a real-world difficulty, particularly with patients with impaired ambulation. Data on rates of reintervention and amputation may be affected by which patients were followed up and also cannot account for patients who received procedures at other institutions. In addition, loss of follow-up limits analysis of perioperative and long-term morbidity that may be relevant to patients with CLI. To accommodate low follow-up rates, we analyzed objective outcomes measures, such as periprocedural complications and mortality. Ambulatory status is a relatively subjective assessment, and it is also unclear how much of it may be transiently due to the CLI symptoms. The overall numbers in the nonambulatory group are relatively lower and may account for why there was no difference seen in 30-day mortality. There is also a selection bias for treatment received based on the patient's comorbidities. Lack of lesion length details in the LEB module limits an accurate comparison between PVI and LEB based on ambulatory status.
CONCLUSIONS
In the VQI, patients received PVI more often than LEB for CLI as ambulatory status declined. Impaired ambulatory status was associated with higher mortality, amputation or death, and MALE or death for both PVI and LEB. Limitations in the VQI necessitate larger prospective, randomized clinical studies with close long-term clinical follow-up. 
AUTHOR CONTRIBUTIONS

